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Targeting X-Linked Inhibitor of Apoptosis Protein to
Increase the Efficacy of Endoplasmic Reticulum
Stress-Induced Apoptosis for Melanoma Therapy
Emma L. Hiscutt1,4, David S. Hill1,4, Shaun Martin1, Ryan Kerr1, Andrew Harbottle1, Mark Birch-Machin1,
Christopher P.F. Redfern2, Simone Fulda3, Jane L. Armstrong1,5 and Penny E. Lovat1,5
Melanoma remains notoriously resistant to current chemotherapeutics, leaving an acute need for novel
therapeutic approaches. The aim of this study was to determine the prognostic and therapeutic significance of
X-linked inhibitor of apoptosis protein (XIAP) in melanoma through correlation of XIAP expression with disease
stage, RAS/RAF mutational status, clinical outcome, and susceptibility to endoplasmic reticulum (ER) stress-
induced cell death. XIAP expression and N-RAS/B-RAF mutational status were retrospectively determined in a
cohort of 55 primary cutaneous melanocytic lesions selected and grouped according to the American Joint
Committee on Cancer staging system. Short hairpin RNA interference of XIAP was used to analyze the effect of
XIAP expression on ER stress-induced apoptosis in response to fenretinide or bortezomib in vitro. The results
showed that XIAP positivity increased with progressive disease stage, although there was no significant
correlation between XIAP positivity and combined N-RAS/B-RAF mutational status or clinical outcome.
However, XIAP knockdown significantly increased ER stress-induced apoptosis of melanoma cells in a caspase-
dependant manner. The correlation of XIAP expression with disease stage, as well as data showing that XIAP
knockdown significantly increases fenretinide and bortezomib-induced apoptosis of metastatic melanoma
cells, suggests that XIAP may prove to be an effective therapeutic target for melanoma therapy.
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INTRODUCTION
Malignant melanoma, the most aggressive form of skin
cancer, represents a significant and growing public health
burden, with an increased incidence in developed countries
that has risen faster than any other malignancy over the past
40 years (Thompson et al., 2005). Prognosis and patient
survival is strongly associated with tumor thickness, ulcera-
tion, and extent of metastases; although early-stage tumors
with a Breslow thickness ofo1mm are largely cured through
surgical excision alone, patient survival rates fall once
metastases occur, resulting in 5-year survival rates of
o11% for those with distant metastases (Balch et al.,
2001). Treatment of metastatic disease is virtually futile as
most melanomas at this stage are resistant to current chemo-
and immunotherapy, emphasizing the acute demand for a, to
our knowledge, previously unreported therapeutic approach.
Resistance to current chemotherapeutic regimes likely results
from the notorious resistance of most melanoma tumor cells
to apoptosis (programmed cell death).
One mechanism by which melanomas may acquire
resistance to apoptosis is by overexpression of one or more
of the inhibitor of apoptosis protein (IAP) family. The IAPs
function as important regulators of apoptosis through their
inhibitory effect on caspases (cysteine-dependent aspartyl-
specific proteases), the principle executioners of apoptosis
(Emanuel et al., 2008). In particular, X-linked inhibitor or
apoptosis protein (XIAP) is overexpressed in melanoma cell
lines (Kluger et al., 2007) as well as in primary cutaneous and
metastatic melanoma tissue (Kluger et al., 2007; Emanuel
et al., 2008), and has therefore become increasingly
relevant to the pathogenesis of melanoma (Chawla-Sarkar
et al., 2004; Emanuel et al., 2008). XIAP is a potent inhibitor
of caspases 3, 7, and 9, and is thus able to block apoptosis
mediated through both extrinsic death-receptor ligation
and intrinsic activation of mitochondria-mediated pathways
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(Schimmer et al., 2006). As overexpression of XIAP in
melanoma cells in vitro confers resistance to multiagent
chemotherapy (Chawla-Sarkar et al., 2004), increased levels
of XIAP in vivo may partly explain why melanoma is resistant
to apoptosis induced by current chemotherapeutic drugs.
Clinically, strategies targeting XIAP are in development, and
include XIAP antisense oligonucletides that are in clinical
trials (Dean et al., 2009), and small-molecule inhibitors that
are in preclinical development (Zobel et al., 2006; Vucic and
Fairbrother, 2007).
Mechanisms regulating XIAP expression in melanoma are
not well understood; however, recent reports have identified an
indirect link between activated RAS/RAF signaling and XIAP
expression (Notarbartolo et al., 2005; Ueda and Richmond,
2006). Activating mutations in N-RAS or B-RAF are present in
the majority of cutaneous melanomas (Davies et al., 2002;
Omholt et al., 2002; Dong et al., 2003; de Snoo and Hayward,
2005) and are implicated in melanoma development as well
as resistance to apoptosis (Gray-Schopfer et al., 2007). Never-
theless, the precise mechanisms by which this pathway confers
chemoresistance are not defined. In addition, we have recently
established that targeting the endoplasmic reticulum (ER)
to generate ER stress induces apoptosis of melanoma cells
both in vitro and in vivo (Lovat et al., 2008; Hill et al., 2009).
We have identified fenretinide and bortezomib as two, to our
knowledge, previously unreported ER stress-inducing agents
capable of inducing apoptosis through caspase-dependent
mechanisms (Lovat et al., 2000; Poulaki et al., 2007); never-
theless, their efficacy may be limited in melanoma by XIAP
overexpression.
To validate XIAP as a therapeutic target in melanoma, the
aims of this study were to evaluate the prognostic significance
of XIAP expression in relation to disease stage, RAS/RAF
mutational status, and clinical outcome, and to test the hypo-
thesis that inhibition of XIAP increases the sensitivity of meta-
static melanoma cells to ER stress-induced death. Defining
the role of XIAP in melanoma progression and chemoresis-
tance will therefore facilitate the design of a more effective
drug combination for the clinical treatment of metastatic
melanoma.
RESULTS
Clinicopathological features of patient specimens
A total of 55 melanocytic samples were collected from 25
male and 29 female patients who together had a median age
of 54 years (Table 1). The majority of samples originated from
the limbs and trunk, with very few from the head and neck
region. Melanoma samples consisted mainly of the superficial
spreading subtype, with nine nodular melanomas and one
acral lentiginous melanoma. At diagnosis, the majority of
patients presented with stage I or II disease; however, four
patients had metastases at presentation. Subsequently, 13
patients went on to develop metastatic disease between 4
months and 512 years after initial presentation. The 5-year
follow up data were available for the majority of melanoma
cases, with 3-year follow-up data for three cases of early-
stage IA disease (p0.5mm Breslow thickness). In all, 11
patients died from metastatic melanoma and the remaining
patients with metastatic disease were monitored for up to
7 years.
XIAP expression in metastatic melanoma cell lines and primary
melanocytes
Expression of XIAP was evaluated in primary human
melanocytes and the metastatic melanoma cell lines CHL-1,
A375, SK MEL-28, and WM266-4 by western blotting. Results
Table 1. Patient demographic data
Number of cases
Age (years)1
o54 26
X54 28
Gender
Male 25
Female 29
Tumor location
Head and neck 4
Trunk/abdomen 22
Limbs 29
Melanocytic lesions
Benign nevi 6
In situ melanoma 7
Superficial spreading 32
melanoma
Nodular melanoma 9
Acral lentiginous 1
melanoma
Melanoma Breslow thickness (mm)
0 7
o1.0 11
1.01–2.0 9
2.01–4.0 14
44.0 8
AJCC stage
0 7
IA and IB 20
IIA, IIB, and IIC 18
IIIA and IIIB 4
IVA, IVB, and IVC 0
Abbreviation: AJCC, American Joint Committee on Cancer, 2001.
1Median value.
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showed that although low levels of XIAP were detectable in
primary melanocytes, XIAP expression was increased in all
metastatic melanoma cell lines (Figure 1).
XIAP expression in primary cutaneous melanoma and benign
melanocytic nevi
To determine whether or not increased XIAP expression
correlates with melanoma disease stage in vivo, immunohis-
tochemistry for XIAP expression was evaluated on formalin-
fixed, paraffin-embedded (FFPE) tissue derived from our
cohort of 55 patient samples. XIAP expression within indi-
vidual samples was indicated by deep pink staining to
distinguish from brown melanin pigment often observed in
melanocytic tumors; expression was compared with a no-
primary antibody control from a consecutive tissue section.
Where XIAP staining was detected, XIAP positivity was
heterogeneous throughout the tumor, but with no consistent
localization to any particular region.
Results showed a trend for increased XIAP expression in
tumors, with increasing Breslow thickness being greater in
superficial spreading malignant melanoma with a Breslow
thickness of 42mm compared with expression in thinner
tumors and benign compound nevi (Figure 2a–d). At higher
magnification, the localization of XIAP was confined in
the cytoplasm of tumor cells (Figure 2i). Importantly, in the
majority of samples, lymphocytes and other cells within
the skin were negative for XIAP staining.
XIAP is frequently overexpressed in late-stage primary
cutaneous melanoma
Analysis of XIAP staining in all 55 samples of this patient
cohort, grouped according to the 2001 American Joint
Committee on Cancer (AJCC) staging system, confirmed that
the median XIAP positivity for each group, represented by the
horizontal lines in Figure 3, increased with progressive stage.
Each data point was derived from the mean percentage of
cells defined visually by light microscopy as positive for
XIAP, within 10 different fields of view for each sample.
There was a significant effect of stage (ordinal predictor) on
the percentage of XIAP-positive cells in patient samples
(generalized linear model, robust estimator; Wald w2 122.8, 6
d.f., Po0.001), with stage II differing significantly from
benign nevi (simple contrasts, Wald w2 4.182, Po0.05;
Figure 3). Patient survival decreased with increasing stage at
diagnosis (Table 1), from 70% of patients surviving with stage
Ib to 25% of patients surviving with stage III. For these disease
stages combined, there was no significant relationship
between the percentage of XIAP-positive cells and death or
survival (Mann–Whitney U11,19¼87, P¼0.45).
Correlation of N-RAS and B-RAF mutations with
clinicopathological parameters and XIAP expression
Tissue sections were single-nucleotide polymorphism (SNP)
genotyped for the presence of activating mutations in N-RAS
and B-RAF; of the 49 melanoma samples in this study, 3 were
N-RASG61L mutated, 5 were N-RASG61A mutated, and 14
were B-RAFV600E mutated. In addition, there was one benign
nevus with an N-RASG61L mutation and two benign nevi with
B-RAFV600E mutations (Table 2). The B-RAFV600D mutation
was not present in any of the samples tested. Statistical
comparison using Mann–Whitney analysis revealed that there
was no significant relationship between mutational status
(combined N-RAS and B-RAF) and XIAP positivity, either for
all stages combined (Mann–Whitney U25,30¼ 276.5, P¼
0.094) or within AJCC stages Ib, II, or III (Mann–Whitney
U20,22¼ 178.5, P¼0.295).
Modulation of XIAP expression to increase ER stress-induced
apoptosis in response to fenretinide and bortezomib
To test the hypothesis that inhibition of XIAP increases the
efficacy of ER stress-induced cell death in response to
fenretinide or bortezomib, A375 cells stably expressing XIAP
short hairpin RNAs (shRNAs) were generated and their
sensitivity to apoptosis was analyzed in response to 24 hours
of treatment with clinically achievable concentrations of
fenretinide, bortezomib, or, as a positive control for ER stress,
thapsigargin. Western blotting confirmed efficient knock-
down of XIAP in a clone expressing XIAP shRNA, compared
with expression in untransfected cells or cells transfected
with either a scrambled control sequence or an empty vector
(Figure 4ai). XIAP knockdown resulted in a significant
increase in apoptosis in response to fenretinide, bortezomib
(Po0.001), and thapsigargin (Po0.01), compared with
untransfected cells or cells transfected with a scrambled
sequence (Figure 4aii, one-way analysis of variance).
Furthermore, apoptosis was dependent on caspase activation,
as shown by the reduction of apoptosis in the presence of the
pan-caspase inhibitor carbobenzoxyl-valyl-alanyl-aspartyl-
[o-methyl]-fluoromethyl-ketone and the inhibition of cas-
pase-3 cleavage (Figure 4a and b). Similar results were also
observed in CHL-1 cells (see Supplementary Figure S1 online).
Conversely, clinically achievable concentrations of the
current melanoma therapeutic temozolomide did not
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Figure 1. Expression of X-linked inhibitor of apoptosis protein (XIAP) in
primary melanocytes and metastatic melanoma cell lines. (a) Representative
western blots of XIAP and b-actin expression in primary melanocytes (11 Mel)
and metastatic melanoma cell lines CHL-1, A375, SK MEL-28, and WM266-4.
(b) Relative XIAP expression levels in primary melanocytes and metastatic
melanoma cell lines quantified relative to b-actin expression to correct for
loading error. Each bar is the mean±SD of three replicate experiments.
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promote apoptosis of A375 or CHL-1 cells, either in control
cells or in cells expressing XIAP shRNA (Figure 4c and
Supplementary Figure S1 online).
DISCUSSION
With a growing incidence of chemotherapy-resistant malig-
nant melanoma worldwide, a desperate need for, to our
knowledge, previously unreported and more effective ther-
apeutic strategies exists. XIAP was recently identified as a
potential prognostic indicator because of its overexpression
in melanoma (Kluger et al., 2007; Emanuel et al., 2008), and
several studies have highlighted the importance of this
protein for the resistance of other cancer types to chemother-
apy (LaCasse et al., 2006; Vogler et al., 2009). In this study
we determined the potential of XIAP as a therapeutic target in
melanoma, and showed a significant association between
increased XIAP expression and late-stage primary cutaneous
melanoma, as well as the ability of XIAP knockdown to
significantly enhance fenretinide and bortezomib-induced
apoptosis of metastatic melanoma cells.
Retrospective selection of patient samples to include a
range of thin and thick primary melanoma tumors, with a
representative proportion of both nonmetastasizing and
metastasizing forms, allowed for the correlation of XIAP
expression with melanoma cancer stage. Consistent with
previous observations, we report a trend for increased XIAP
expression with increasing Breslow thickness of a tumor
(Emanuel et al., 2008). However, occasionally a melanoma
with a thin Breslow thickness will metastasize; to additionally
account for the spread of disease that is not considered by
analyzing Breslow thickness alone, we investigated the
correlation between XIAP expression, defined as the propor-
tion of tumor cells positive for XIAP staining, and cancer stage
according to the 2001 AJCC staging system. Our finding was
that XIAP expression significantly correlated with cancer
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Figure 2. X-linked inhibitor of apoptosis protein (XIAP) expression in human primary cutaneous melanoma compared with controls. Immunohistochemical
analysis of XIAP or control (no primary antibody) in (a, e) a compound nevus, (b, f) early-stage superficial spreading malignant melanoma (SSMM) with a Breslow
thickness (BT) ofo1mm, (c, g, i, j) later-stage SSMM with a BT of 2–4mm, and (d, h) later-stage SSMM with a BT of44mm. Note the white retraction artifact
around several melanoma cells commonly observed after tissue fixation. Scale bars for a–h ¼50 mm, and for i, j¼ 25 mm.
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Figure 3. X-linked inhibitor of apoptosis protein (XIAP) expression increases
with progressing American Joint Committee on Cancer (AJCC) disease stage.
Mean XIAP-positive tumor cells (derived as a proportion of all cells within 10
fields of view) in patient cohort (55) derived from benign nevi or in situ
melanoma (stage 0) or from AJCC stage Ia, Ib, II, and III primary cutaneous
melanomas. The median percentage of XIAP positivity is represented by the
horizontal line.
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Table 2. XIAP expression and clinicopathological characteristics
Sample Tumor type
Breslow
thickness (mm)
AJCC stage
at diagnosis Metastasis1
Death due
to MM2
Mean %
XIAP-positive cells3
B-RAF/
N-RAS4
1 Nevus 0 0 0.12 V600E
2 Nevus 0 0 0 G61L
3 Nevus 0 0 0.02 V600E
4 Nevus 0 0 0
5 Nevus 0 0 0.01
6 Nevus 0 0 0.03
7 In situ MM 0 0 0 0
8 In situ MM 0 0 0 0.18
9 In situ MM 0 0 0 0.28
10 In situ MM 0 0 0 0.01
11 In situ MM 0 0 0 0
12 In situ MM 0 0 0 0
13 In situ MM 0 0 0 0.18
14 SSMM o1.0 IA 0 0 0
15 SSMM o1.0 IA 0 0 0.23 V600E
16 SSMM o1.0 IA 0 0 0.09
17 SSMM o1.0 IA 0 0 0.09
18 SSMM o1.0 IA 0 0 0 G61A
19 SSMM o1.0 IA 0 0 0
20 SSMM o1.0 IA 0 0 0.41
21 SSMM o1.0 IA 0 0 5.23
22 SSMM o1.0 IA 0 0 0.01
23 SSMM o1.0 IA 0 0 0.22
24 SSMM o1.0 IA 0 0 1.34
25 SSMM 1.01–2.0 IB 0 0 0
26 SSMM 1.01–2.0 IB 0 0 0.11 V600E
27 SSMM 1.01–2.0 IB 0 0 0 V600E
28 SSMM 1.01–2.0 IB 0 0 0.48 V600E
29 SSMM 1.01–2.0 IB 0 0 0.35
30 SSMM 1.01–2.0 IA 0 0 0.27
31 SSMM 2.01–4.0 IIA 0 0 0.14 V600E
32 SSMM 2.01–4.0 IIA 0 0 5.08
33 NMM 2.01–4.0 IIA 0 0 7.3 G61L
34 SSMM 2.01–4.0 IIA 0 0 0
35 NMM 2.01–4.0 IIA 0 0 1.02 G61L
36 NMM 44.0 IIC 0 0 1.99
37 NMM 44.0 IIC 0 0 35.13
38 SSMM 44.0 IIC 0 0 2
39 NM 44.0 IIIC 1 0 46.67 V600E
40 NM 2.01–4.0 IIA 1 0 0.09 G61A
41 SSMM 2.01–4.0 IIA 1 0 71.04 V600E
42 SSMM 2.01–4.0 IIB 1 0 0.34 V600E
43 SSMM 2.01–4.0 IIA 1 0 0.81 G61A
Table 2 continued on the following page
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stage, suggesting that XIAP is a useful prognostic marker. This
analysis did not correlate primary tumors that subsequently
metastasized, which needs to be taken into consideration to
fully evaluate XIAP expression as a prognostic marker.
Oncogenic RAS/RAF signaling is now well characterized
as a mechanism contributing to the establishment of
melanoma (Fecher et al., 2007). Mutations that activate
either RAS or RAF, in particular N-RASG61L/A and B-RAFV600E,
have been identified in a large proportion of melanomas and
are implicated in melanoma development and resistance to
apoptosis (Gorden et al., 2003; Garnett and Marais, 2004).
Recent reports identifying XIAP as an indirect target of RAS/
RAF signaling suggest that XIAP upregulation in melanoma
may be related to the presence of oncogenic mutations in this
pathway (Notarbartolo et al., 2005; Ueda and Richmond,
2006). To test this hypothesis, SNP genotyping assays were
used to identify the most commonly occurring N-RAS and
B-RAF mutations in tissue from primary melanoma samples.
There was no significant correlation between the N-RAS or
B-RAF mutational status of tumors and the level of XIAP
expression; nevertheless, we cannot exclude the possibility
that other rare activating mutations influencing RAS/RAF
signaling may have been present that could influence XIAP
expression.
The findings of a significant association of XIAP expression
with poor prognosis, as well as data showing that XIAP
knockdown significantly increases fenretinide and bortezo-
mib-induced apoptosis of metastatic melanoma cells in a
caspase-dependent manner, suggests that XIAP may prove to
be an effective therapeutic target for melanoma treatment. A
recent clinical trial of AEG35156 (Aegera Therapeutics;
Schimmer et al., 2009) for the treatment of acute myeloid
leukemia showed that XIAP inhibition was generally well
tolerated, therefore suggesting that combining an ER stress-
inducing agent, such as fenretinide or bortezomib, with an
inhibitor of XIAP or a small-molecule antagonist (Vogler
et al., 2009) could represent a more effective therapeutic
strategy for the treatment of metastatic melanoma.
MATERIALS AND METHODS
Patients and specimens
All cases were selected retrospectively from the Department of
Pathology at the Royal Victoria Infirmary, Newcastle Upon Tyne,
UK, and consisted of a total of 55 melanocytic lesions, including
benign nevi (n¼ 6) and primary cutaneous malignant melanomas
(n¼ 49; ranging from Breslow thickness 0.2 to 9.0mm and Clark level
I–V), with or without ulceration (Table 1). Cases were selected to
encompass a range of disease stages (as defined by the 2001 AJCC),
and for which clinical and histopathological follow-up was available
(ranging from 0.5 to 7.0 years). Cases included thin, intermediate, and
thick nonmetastasizing primary tumors, as well as intermediate and
thick primary tumors, all of which proceeded to metastasize. Archival
FFPE tissue blocks were collected after ethical approval from the
research ethics committee of Northumberland National Health Service
and with written, informed patient consent obtained as appropriate,
and the study was performed in accordance with the Declaration of
Helsinki Principles. Exclusion criteria included patients of age o16
years, pregnancy at the time of surgical treatment, and those with an
immune-modifying disease or who had used immune-modifying drugs
within 3 months of their surgical treatment. Clinical end point was time
to disease-specific death.
Evaluation of activating mutations of N-RAS and B-RAF in the
patient cohort
DNA was extracted from FFPE tissue blocks using QIAamp
DNA FFPE Tissue Kit (Qiagen, Crawley, UK) according to the
Table 2. Continued
Sample Tumor type
Breslow
thickness (mm)
AJCC stage
at diagnosis Metastasis1
Death due
to MM2
Mean %
XIAP-positive cells3
B-RAF/
N-RAS4
44 ALM 2.01–4.0 IIA 1 0 3.18
45 SSMM 1.01–2.0 IIA 1 1 0.04 G61A
46 SSMM 1.01–2.0 IB 1 1 42.5 V600E
47 SSMM 1.01–2.0 IB 1 1 1.53 V600E
48 SSMM 2.01–4.0 IIIC 1 1 16.99 V600E
49 SSMM 2.01–4.0 IIB 1 1 0 G61L
50 NM 2.01–4.0 IIA 1 1 0.34
51 SSMM 44 IIC 1 1 0.61 G61A
52 NM 44 IIIC 1 1 2.35
53 NM 2.01–4.0 IB 1 1 7.47 V600E
54 SSMM 44 IIC 1 1 26.16 V600E
55 NM 44 IIIB 1 1 2.65 V600E
Abbreviations: AJCC, 2001 American Joint Committee on Cancer; ALM, acral lentiginous melanoma; MM, malignant melanoma; NM, nodular melanoma;
SSMM, superficial spreading malignant melanoma; XIAP, X-linked inhibitor of apoptosis protein.
1Metastasis: 0, patient did not develop metastases during follow-up period; 1, patient went on to develop metastases after diagnosis.
2Death due to MM: 0, patient did not die from disease; 1, patient died from melanoma after diagnosis.
3Mean % XIAP-positive cells: the percentage of tumor cells expressing XIAP (mean of 10 fields of view).
4B-RAF/N-RAS SNP mutations: B-RAF included V600E and V600D, and N-RAS included G61L and G61A.
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manufacturer’s protocol. Immediate tissue sections to those taken for
routine histology were taken for DNA extraction. PCR amplification
and sequencing of the two most common N-RAS codon-61 SNPs on
exon 2, N-RAS G61L and G61A, as well as the SNPs for B-RAF
V600D and V600E mutations (Davies et al., 2002; Omholt et al.,
2002) were performed using custom-made primers and probes
(see Supplementary Table S1 online; Custom TaqMan SNP
Genotyping Assay; Applied Biosystems, Warrington, UK). Quantita-
tive PCR was performed with Chromo4 (MJ/Bio-Rad, Hemel
Hempstead, Hertfordshire, UK), using Faststart Universal Probe
Master (Roche Diagnostics, Burgess Hill, UK).
XIAP immunohistochemistry
Patient tumor specimens (6 to 7mm consecutive FFPE tissue sections)
were placed onto (3-aminopropyl)triethoxysilane (APES; Sigma-
Aldrich, Dorset, UK)-coated glass slides and baked overnight at
37 1C. Sections were deparaffinized in Histo-Clear (30minutes;
Sigma-Aldrich) and rehydrated in a graded series of ethanol before
H2O. Slides were heated at 100 1C in a microwave oven in 0.01M
Tris-HCl pH 7.6 for 20minutes and cooled to room temperature.
After permeabilization for 10minutes with 0.2% Triton X-100 in
phosphate-buffered saline, sections were then incubated in 3%
hydrogen peroxide in water for 10minutes. After incubation with 5%
horse serum in phosphate-buffered saline containing 0.05% Tween-
20 for 20minutes at room temperature, sections were incubated with
monoclonal anti-XIAP (BD Biosciences, Oxford, UK) diluted 1:250
in phosphate-buffered saline with 2% albumin and 5% horse serum
at 4 1C for 72 hours (Emanuel et al., 2008). Antibody detection was
performed using a mouse IgG ABC elite Vectastain Kit (Vector Labs,
Peterborough, UK) and developed with Vector VIP to give a deep-
pink stain (Vector Labs). Finally, sections were counterstained using
hematoxylin, dehydrated in increasing concentrations of ethanol
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Figure 4. X-linked inhibitor of apoptosis protein (XIAP) inhibits endoplasmic reticulum (ER) stress-induced apoptosis in a caspase-dependent manner.
A375 cells were untransfected (C) or transfected with either a scrambled control sequence (SC), empty vector (EV), or XIAP shRNA (X) before treatment
with 12mM fenretinide (F), 200 nM bortezomib (B), or 7.5 mM thapsigargin (T) in the presence or absence of 25mM z-VAD for 24 hours. (a) Percentage of apoptosis;
each bar is the mean of three replicates ± SD; **Po0.01, ***Po0.001. (ii) Western blots for XIAP or b-actin expression. (b) Western blots for cleaved
caspase-3 or b-actin expression. (c) A375 cells (as above) were treated with 50 mM temozolomide (Te) for 24 hours. Data are expressed as percentage of
apoptosis; each bar is the mean of three replicates ± SD.
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solution, then cleaned in Histo-Clear, and mounted in di‘n’butyl
phthalate in xylene before visualization.
All immunostained slides were coded so that clinicopathological
data could not be directly correlated. Staining was visualized by light
microscopy; 10 fields from XIAP-stained sections were system-
atically selected within the tumor, and images were captured and
analyzed using Leica QWin software (Leica Microsystems, New-
castle upon Tyne, UK). The number of positively stained cells and
the total number of cells were counted to allow calculation of the
proportion of tumor cells staining positive.
Cell culture, drug treatment, and analysis of apoptosis
Melanoma cell lines, CHL-1, A375, and WM266-4 (ATCC), were
cultured in DMEM (Lonza, Cambridge, UK) supplemented with 10%
fetal bovine serum in a humidified incubator at 37 1C/5% CO2 as
previously described (Corazzari et al., 2007). Melanocytes were
obtained from human foreskin, isolated from fibroblasts and
keratinocytes by selective trypsinization (Todd and Reynolds,
1998), confirmed by immunostaining for the melanocyte differentia-
tion antigen Melan-A (Abcam plc, Cambridge, UK), and cultured
in medium 254 supplemented with human melanocyte growth
supplement-2 according to the manufacturer’s specifications
(Invitrogen, Paisley, UK). Fenretinide (Janssen-Cilag High Wycombe,
UK), bortezomib (Janssen-Cilag), thapsigargin (Sigma-Aldrich),
temozolomide (OSI Pharmaceuticals, Oxford, UK), or carboben-
zoxyl-valyl-alanyl-aspartyl-[o-methyl]-fluoromethyl-ketone (Prome-
ga, Southampton, UK) were added to cells in ethanol (fenretinide)
or DMSO (bortezomib, thapsigargin, or carbobenzoxyl-valyl-
alanyl-aspartyl-[o-methyl]-fluoromethyl-ketone) with an equal vo-
lume of vehicle used to treat control cells. Flow cytometry of
propidium iodide-stained cells was used to estimate the level of cell
death or apoptosis by measuring the percentage of cells in the sub-
G1 fraction (Corazzari et al., 2007).
Retroviral transfection for shRNA interference of XIAP
For shRNA-expressing vectors against XIAP, the target sequence
50-GTGGTAGTCCTGTTTCAGC-30 (Burstein et al., 2004) was incor-
porated into the following oligos: fw, 50-GATCCCGTGGTAGTCCT
GTTTCAGCTTCAAGAGAGCTGAAACAGGACTACCACTTTTTGGA
AA-30 and rev, 50-AGCTTTTCCAAAAAGTGGTAGTCCTGTTTCAGCT
CTCTTGAAGCTGAAACAGGACTACCACGGG-30. Oligos were an-
nealed and cloned into the pRETROSUPER vector (Brummelkamp
et al., 2002) using BglII and HindIII, propagated in supercompetent
XL1-Blue E. coli cells (Stratagene, Stockport, UK) and isolated using a
HiSpeed plasmid Maxi kit (Qiagen) according to the manufacturer’s
instructions. Using lipofectamine 2000 (Invitrogen), 1mg of purified
plasmid was transfected into pRT67 mouse fibroblast packaging cells
to produce live virus. Resulting supernatant containing the virus was
then used to transduce A375 and CHL-1 human melanoma cells and
stable clones were selected using 1mgml–1 puromycin (Invitrogen).
WESTERN BLOTTING
Total protein was extracted from cell pellets into lysis buffer
(100mM Tris-HCl, pH 7.4, 100mM NaCl, 2mM EDTA, 25mM
NaF, 0.1% (v/v) Triton X-100, 1mM benzamidine, 0.1mM
Na3VO4, and complete protease inhibitor cocktail (Roche
Diagnostics), separated by electrophoresis through 4–20%
SDS-PAGE gels (20 mg per lane; Invitrogen), and transferred
to polyvinylidene difluoride membranes (Amersham
Biosciences, Little Chalfont, UK) as previously described
(Armstrong et al., 2007). Blots were probed with antibodies to
XIAP (Cell Signaling Technology, Hitchin, UK; diluted
1:1,000), cleaved caspase-3 (Cell Signaling Technology;
diluted 1:1,000), and b-actin (Sigma-Aldrich; diluted
1:5,000). The binding of primary antibodies was detected
with secondary peroxidase-conjugated antibodies (Upstate
Biotechnology, Vector Labs; diluted 1:2000) and visualized
using the enhanced chemiluminescence plus system (Amer-
sham Biosciences).
Statistical analysis
Statistical analyses were carried out using SPSS version 15
(SPSS, Chicago, IL) or Graphpad Prism version 5 (Graphpad
Software, La Jolla, CA). In the immunohistochemistry studies,
data for the percentage of XIAP-positive cells with AJCC stage
as ordinal predictor were analyzed with a generalized linear
model using a log link function and normal distribution with
a robust estimator; simple contrasts were used to compare
each stage with data for the first category in the analysis
(benign nevus). An intercept (not significant in the initial
analysis) was not included in the final model (fitted model
compared with null model: likelihood ratio w2 13.335, 6 d.f.,
P¼0.038). Relationships between XIAP positivity and N-
RAS/B-RAF mutational status were examined using Man-
n–Whitney tests. Data for apoptosis in cells transfected with
XIAP shRNA were analyzed by one-way analysis of variance
with post hoc Bonferroni test.
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